Compare Quest Diagnostics Inc (DGX) vs Western Union Co (WU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Quest Diagnostics Inc vs Western Union Co — how do they compare? Quest Diagnostics Inc trades at $231.73 (market cap $25.48B), while Western Union Co trades at $6.33 (market cap $1.97B). The key difference: Quest Diagnostics Inc is far larger — about 12.9× Western Union Co's market cap, and Western Union Co pays the higher dividend (14.85%). Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Western Union Co for 95 Days on average.
| DGX | WU | |
|---|---|---|
Market Cap | $25.48B | $1.97B |
Volume | 941,866 | 10,235,212 |
Sector | Health | Financials |
52-Week High | $247.45 | $10.28 |
52-Week Low | $173.49 | $5.90 |
Typical Hold Time | 56 Days | 95 Days |
Enterprise Value | $31.23B | $1.88B |
Dividend Yield | 1.49% | 14.85% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% on the day, with the stock showing strong fundamental performance including three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.04B in 2025. Technical indicators signal bearish momentum with the current price near key support at $226, while the company maintains solid profitability with 9.19% net income margin and 14.35% ROE. Recent developments include positive clinical study results and a new partnership with Apple Health app for lab testing integration.
The investment outlook remains positive with analyst consensus target of $250 representing 10% upside potential, though Medicare reimbursement cuts pose near-term headwinds. Growth drivers include advanced diagnostics expansion and consumer testing demand, balanced against technical weakness and regulatory uncertainty. The stock offers value with reasonable P/E of 24.1 and consistent dividend payments.
Western Union (WU) trades at $6.11, down 0.49% on the day, with the stock showing bearish technical signals and mixed fundamental performance. Recent earnings show two misses in the last three quarters, though the company maintains strong profitability metrics including a 43.97% ROE and 9.79% net margin. The $200 million Beyond Efficiency Plan aims to revive profitability by 2027, while the pending Intermex acquisition faces regulatory hurdles in California.
WU presents a value opportunity with low P/E (5.1) and P/S (0.5) ratios, but faces execution risks from margin pressures and acquisition integration. Analyst consensus is cautious with a $6.86 price target, representing 12% upside, though recent technical weakness and earnings volatility warrant careful monitoring of the turnaround plan's progress.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Quest Diagnostics Inc
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →About Western Union Co
Western Union provides domestic and international money transfers through its global network of about 500,000 outside agents. It is the largest money transfer company in the world and one of only a few companies with a truly global agent network.
Read more on WU →
